

DAFTAR PUSTAKA

- AMALIA, M., HIDAYATI, P.H., EKA YANTI, A.K., VITAYANI, S. and GAYATRI, S.W. (2023) Karakteristik Pasien Sirosis Hepatis. *UMI Medical Journal*, 8(1), pp. 53–61.
- AMES, J.B., DJERBOUA, M., TERRAULT, N.A., BOOTH, C.M. and FLEMMING, J.A. (2022) Rising Healthcare Costs and Utilization among Young Adults with Cirrhosis in Ontario: A Population-Based Study. *Canadian Journal of Gastroenterology and Hepatology*, 2022,
- ANDREW, S., KATRINA, B. and CHRISTOPHER, B. (2019) Cirrhosis : Diagnosis and Management. *Am Fam Physician*, pp. 759–770.
- ARCIA-TSAO, G., SANYAL AJ, GRACE ND and CAREY W (2007) Practice Guidelines Committee of the American Association for the Study of Liver Diseases : Practice Parameters Committee of the American College of Gastroenterology. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. *Hepatology*, 46(922–38).
- BATALLER R, B. DA (2005) Liver fibrosis. *J Clin Invest*, 115(2), pp. 209–18.
- BRAET F, W.E. (2002) Structural and functional aspects of liver sinusoidal endothelial cell fenestrae: a review. *Comp Hepatol*, 23(1).
- CARRIER, P., DEBETTE-GRATIEN, M., JACQUES, J. and LOUSTAUD-RATTI, V. (2019) Cirrhotic patients and older people. *World Journal of Hepatology*, 11(9), pp. 663–677.
- CASAFONT MORENCOS F and DE LAS HERAS CASTAÑO G, MARTÍN RAMOS L, LÓPEZ ARIAS MJ, LEDESMA F, P.R.F. (1996) Small bowel bacterial overgrowth in patients with alcoholic cirrhosis. *Dig Dis Sci*, 41(3), pp. 552–6.
- CHILD CG and JG, T. (1964) Surgery and portal hypertension. *Major Probl Clin Surg*, 1, pp. 1–85.
- COPPEL, S., MATHUR, K., EKSER, B., PATIDAR, K.R., ORMAN, E., DESAI, A.P., VILAR-GOMEZ, E., KUBAL, C., CHALASANI, N., NEPHEW, L. and GHABRIL, M. (2020) Extra-hepatic comorbidity burden significantly increases 90-day mortality in patients with cirrhosis and high model for endstage liver disease.

- BMC Gastroenterology*, 20(1), pp. 1–11.
- COUNCIL ON FAMILY HEALTH (2004).
- DEACIUC IV, NB, D'SOUZA, F, FORTUNATO DB, HILL TG, SARPHIE CJ, M. (2001) Alcohol-induced sinusoidal endothelial cell dysfunction in the mouse is associated with exacerbated liver apoptosis and can be reversed by caspase inhibition. *Hepatol Res*, 19(1).
- DEVARBHAVI, H. and SUMEET K. ASRANI, JUAN PABLO ARAB, YVONNE AYERKI NARTEY, ELISA POSE, P.S.K. (2023) Global burden of liver disease: 2023 update. *Journal of Hepatology*, 79(2), pp. 516–537.
- DIPIRO, J.T., YEE, G.C., HAINES, S.T., NOLIN, T.D., ELLINGROD, V.L. and POSEY, L.M. (2023) *DiPiro's Pharmacotherapy: A Pathophysiologic Approach*, 12th Edition. USA: Mc Graw Hill LLC.
- DRUGBANK (2025) *Drugs*.
- DRUGS.COM (2025) *Drugs Interaction Checker*.
- EZERİŇA, D., TAKANO, Y., HANAOKA, K., URANO, Y. and DICK, T.P. (2018) N-Acetyl Cysteine Functions as a Fast-Acting Antioxidant by Triggering Intracellular H₂S and Sulfane Sulfur Production. *Cell Chemical Biology*, 25(4), pp. 447-459.e4.
- FAROOQ, J., SANA, M.M., CHETANA, P.M., ALMUQBIL, M., PRABHAKAR BHAT, N., SULTANA, R., KHAISER, U.F., MOHAMMED BASHEERUDDIN ASDAQ, S., ALMALKI, M.E.M., MOHAMMED SAWADI KHORMI, A., AHMAD ALBRAIKI, S. and ALMADANI, M.E. (2023) Polypharmacy in chronic liver disease patients: Implications for disease severity, drug-drug interaction, and quality of life. *Saudi Pharmaceutical Journal*, 31(8), p. 101668.
- FERYA CELIK, BEKTAS, H. and YOUNOSSI, Z. (2023) Psychometric Properties of the Chronic Liver Disease Questionnaire in Patients with Chronic Liver Disease. *Journal of Basic and Clinical Health Sciences*, 7(2), pp. 671–683.
- FRANZ, C.C., EGGER, S., BORN, C., RÄTZ BRAVO, A.E. and KRÄHENBÜHL, S. (2012) Potential drug-drug interactions and adverse drug reactions in patients with liver cirrhosis. *European Journal of Clinical Pharmacology*, 68(2), pp. 179–188.
- GAZINEO, D., GODINO, L., BUI, V., EL MOUTTAQI, L., FRANCIOSI, E., NATALINO,

- A., CECI, G. and AMBROSI, E. (2021) Health-related quality of life in outpatients with chronic liver disease: a cross-sectional study. *BMC Gastroenterology*, 21(1), pp. 1–9.
- GIORGIO, A, P, AMOROSO G, LETTIERI P, FICO G, DE STEFANO L, FINELLI V, SCALA L, TARANTINO P, PIERRI G, P. (1986) Cirrhosis: value of caudate to right lobe ratio in diagnosis with US. *Radiology*, 161(2), pp. 443–5.
- GREEN GR (1977) Mechanism of hypogonadism in cirrhotic males. *Gut*, 18(10), pp. 843–53.
- HABIBZADEH, F. (2024) Data Distribution: Normal or Abnormal? *Journal of Korean Medical Science*, 39(3), pp. 1–8.
- HALFON P, M, M. and T, P. (2008) FibroTest-ActiTest as a non-invasive marker of liver fibrosis. *Gastroenterol Clin Biol*, 32(6), pp. 22–39.
- HAMADOUK, R.M., ALSHAREIF, E.M., HAMAD, H.M. and YOUSEF, B.A. (2023) The Prevalence and Severity of Potential Drug–Drug Interactions in Internal Medicine Ward at Soba Teaching Hospital. *Drug, Healthcare and Patient Safety*, 15(October), pp. 149–157.
- HANAI, T., NISHIMURA, K., MIWA, T., MAEDA, T., IMAI, K., SUETSUGU, A., TAKAI, K. and SHIMIZU, M. (2023) Prevalence, association, and prognostic significance of polypharmacy and sarcopenia in patients with liver cirrhosis. *JGH Open*, 7(3), pp. 208–214.
- HANSEL, T.T., TAN, A.J., BARNES, P.J. and MIN KON, O. (2008) Anticholinergic bronchodilators. *Asthma and COPD: Basic Mechanisms and Clinical Management*, pp. 615–626.
- HASAN, I., PUTRA, R.P., YUNIHASTUTI, E. and KURNIAWAN, J. (2022) The Validity and Reliability of the Indonesian Version of the Chronic Liver Disease Questionnaire (CLDQ) in Measuring Quality of Life in Patients with Liver Cirrhosis. *Acta Medica Indonesiana*, 54(1), pp. 10–18.
- JEPSEN, P. (2014) Comorbidity in cirrhosis. *World Journal of Gastroenterology*, 20(23), pp. 7223–7230.
- JIBAI, N., KOCH, A., ULMER, T.F., ERDMANN, P., KOECK, J.A. and EISERT, A. (2023) Pharmaceutical Interventions for Inpatients with Liver Cirrhosis and Liver Transplantation: A Systematic Review of Experimental Studies.

- Journal of Clinical Medicine*, 12(22), pp. 1–15.
- JOHN S, T.P. (2015) Hyponatremia in cirrhosis: pathophysiology and management. *World J Gastroenterol*, 21(11), pp. 3197–205.
- KALAITZAKIS, E. (2014) Gastrointestinal dysfunction in liver cirrhosis. *World Journal of Gastroenterology*, 20(40), pp. 14686–14695.
- KEMENKES (2019) *Laporan Provinsi Sumatera Barat Riskesdas 2018*. Jakarta.
- KEMENKES (2023) Menjaga Hati Untuk Kehidupan. *Mediakom*.
- KIM MY and SK., B. (2009) Hyperdynamic circulation in patients with liver cirrhosis and portal hypertension. *Korean J Gastroenterol*, 54(3), pp. 143–8.
- KIM MY, SK, B. and SS, L. (2010) Hemodynamic alterations in cirrhosis and portal hypertension. *Korean J Hepatol*, 16(4), pp. 347–52.
- KOLIOS G, VALATAS V, K.E. (2006) Role of Kupffer cells in the pathogenesis of liver disease. *World J Gastroenterol*, 12(46).
- KOUTNY, F., AIGNER, E., DATZ, C., GENSLUCKNER, S., MAIERON, A., MEGA, A., IGLSEDER, B., LANGTHALER, P., FREY, V., PAULWEBER, B., TRINKA, E. and WERNLY, B. (2023) Relationships between education and non-alcoholic fatty liver disease. *European Journal of Internal Medicine*, 118(July), pp. 98–107.
- LATA J (2012) Hepatorenal syndrome. *World J Gastroenterol*, 18(36), pp. 4978–84.
- LIU, QIANG, WANG, H. and LV, SHENGYIN ZHAO, YANYAN ZHENG, YABIN LI, GUANYU WANG, W. (2024) The Combined Use of Levodopa/Benserazide and Pramipexole Proves Beneficial for Managing Parkinson's Disease. *Actas espanolas de psiquiatria*, 52(6), pp. 769–776.
- MANSOUR, D. and MCPHERSON, S. (2018) Management of decompensated cirrhosis. *Clinical Medicine, Journal of the Royal College of Physicians of London*, 18(2), pp. s60–s65.
- MENG, Y. and JONATHAN P. MAYNARD, KYLIE J. SMITH, MARKUS JUONOLA, ELAINE M. URBINA, TEEMU NIIRANEN, STEPHEN R. DANIELS, BO XI, C.G.M. (2024) Pediatric Blood Pressure and Cardiovascular Health in Adulthood. *Current Hypertension Reports*, pp. 431–450.
- MIMS (2025) *Drug Information*.
- MONTROSE, J.A., DESAI, A., NEPHEW, L., PATIDAR, K.R., GHABRIL, M.S.,

- CAMPBELL, N.L., CHALASANI, N., QIU, Y., HAYS, M.E. and ORMAN, E.S. (2024) Medication burden and anticholinergic use are associated with overt HE in individuals with cirrhosis. *Hepatology Communications*, 8(8),
- MUSTIKA, S., SUSANTO, J.P. and LESMANA, C.R.A. (2023) Association between the severity of liver cirrhosis with quality of life and its impact on clinical practice. *Egyptian Liver Journal*, 13(1), [Online] Available from: doi.org/10.1186/s43066-023-00299-z.
- MUTI, A.F. and ANINDYA, C. (2021) Analysis of Potential Drug-drug Interactions in Liver Cirrhosis Patients. *Jurnal Farmasi Galenika (Galenika Journal of Pharmacy) (e-Journal)*, 7(1), pp. 17–28.
- NAVEAU S, PERLEMUTER G, B.A. (2005) Epidemiology and natural history of cirrhosis. *Rev Prat*, 55(14), pp. 1527–32.
- NIDDK (2023) *Cirrhosis*.
- NOOR, S., ISMAIL, M., HAIDER, I. and KHADIM, F. (2018) Drug-drug interactions in hepatitis patients: Do these interactions matter in clinical perspectives? *Annals of Hepatology*, 17(6), pp. 1001–1011.
- OLKKOLA, K.T. and AHONEN, J. (2001) *Drug interactions*.
- OSNA, N.A., DONOHUE, T.M. and KHARBANDA, K.K. (2017) Alcoholic liver disease: Pathogenesis and current management. *Alcohol Research: Current Reviews*, 38(2), pp. 7–21.
- PALLERIA, C., DI PAOLO, A., GIOFRÈ, C., CAGLIOTI, C., LEUZZI, G., SINISCALCHI, A., DE SARRO, G. and GALLELLI, L. (2013) Pharmacokinetic drug-drug interaction and their implication in clinical management. *Journal of Research in Medical Sciences*, 18(7), pp. 600–609.
- PAPDI (2020) *Penatalaksanaan Di Bidang Ilmu Penyakit Dalam : Panduan Praktik Klinis*.
- PHILIP D and HANSTEN, P.D. (1975) *Drug Interactions : Clinical Significance of Drug-drug Interactions and Drug Effect on Clinical Laboratory Results*.
- PIROVINO M, R, L., BOSS C, KÖCHLI HP and F, M. (1988) Cutaneous spider nevi in liver cirrhosis : capillary microscopical and hormonal investigations. *Klin Wochenschr*, 66(7), pp. 298–302.
- PUGH RN, MURRAY-LYON, JL DAWSON, MC, PIETRONI R, W. (1973) Transection

of the oesophagus for bleeding oesophageal varices. *Br J Surg*, 60(8), pp. 646–9.

RABBA, A.K., ABU HUSSEIN, A.M., ABU SBEIH, B.K. and NASSER, S.I. (2020) Assessing Drug-Drug Interaction Potential among Patients Admitted to Surgery Departments in Three Palestinian Hospitals. *BioMed Research International*, 2020

REGEV A, BERHO M, JEFFERS LJ, MILIKOWSKI C, MOLINA EG, PYRSOPOULOS NT, FENG ZZ, REDDY KR, S.E. (2002) Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. *Am J Gastroenterol*, 97(10), pp. 2614–8.

ROBBY PRATOMO PUTRA (2021) *Uji Kesahihan dan Keandalan Chonic Liver Disease Questionnaire dalam Bahasa Indonesia untuk Mengukur Tingkat Kualitas Hidup Pasien Sirosis Hepatis*. Universitas Indonesia.

ROERECKE, M., VAFAEI, A., HASAN, O.S., CHRYSTOJA, B.R., CRUZ, M., LEE, R., NEUMAN, M.G. and REHM, J. (2019) Alcohol consumption and risk of liver cirrhosis: a systematic review and meta-analysis. *Physiology & behavior*, 114(10)

RUBIN, J.B., SUNDARAM, V. and LAI, J.C. (2020) Gender differences among patients hospitalized with cirrhosis in the United States. *Journal of Clinical Sleep Medicine*, 54(1).

RUTLEDGE, S.M. and ASGHARPOUR, A. (2020) Smoking and liver disease. *Gastroenterology and Hepatology*, 16(12), pp. 617–625.

SAINANI, K.L. (2012) Dealing With Non-normal Data. *PM and R*, 4(12), pp. 1001–1005.

SCAGLIONE, STEVEN., STEPHANIE KLIETHERMES., GUICHAN CAO., DAVID SHOHAM., RAMON DURAZO., AMI LUKE. and MICHAEL L VOLK. (2015) The Epidemiology of Cirrhosis in the United States: A Population-based Study. *J Clin Gastroenterol*, 4(8), pp. 690–6.

SCHUPPAN D, A.N. (2008) Liver cirrhosis. *Lancet*, 371(9615), pp. 838–51.

SHEEN IS and LIAW, Y. (1989) The prevalence and incidence of cholecystolithiasis in patients with chronic liver diseases: a prospective study. *Hepatology*, 9(4), pp. 538–40.

- SOHERWARDI, S., CHOGTU, B. and FAIZAL, P. (2012) Surveillance of the potential drug-drug interactions in the medicine department of a tertiary care hospital. *Journal of Clinical and Diagnostic Research*, 6(7 SUPPL.), pp. 1258–1261.
- STALEVO, J.P. (2023) A pioneering treatment for OFF periods in Parkinsons disease. *Eur J Neurol*, 2, pp. 3–8.
- STROFFOLINI, T., SAGNELLI, E., SAGNELLI, C., MORISCO, F., BABUDIERI, S., FURLAN, C., PIRISI, M., RUSSELLO, M., SMEDILE, A., PISATURO, M. and ALMASIO, P.L. (2020) The association between education level and chronic liver disease of any etiology. *European Journal of Internal Medicine*, 75(December 2018), pp. 55–59.
- SUGIYONO (2020) *Metodologi Penelitian Kuantitatif, Kualitatif dan R & D*.
- SUGIYONO (2007) *Statistika untuk Penelitian*. Bandung: Penerbit Alfabeta Bandung.
- TCHLEPI, H., PW, R., RADIN R and E., G. (2002) Sonography of diffuse liver disease. *J Ultrasound Med*, 21(9), pp. 1033–4.
- USMAN, F.H., BIRMAN, Y. and WAHYUNI, S. (2025) Profil Pasien Sirosis Hepatis di RSUP Dr. M. Djamil Padang Tahun 2021. *Health and Medical Journal*, 7(2), pp. 29–42.
- VAJA, R. and RANA, M. (2023) Drugs and the liver. *Anaesthesia and Intensive Care Medicine*, 24(9), pp. 536–542.
- VAZ, J., STRÖMBERG, U., ERIKSSON, B., BUCHEBNER, D. and MIDLÖV, P. (2020) Socioeconomic and marital status among liver cirrhosis patients and associations with mortality: a population-based cohort study in Sweden. *BMC Public Health*, 20(1), pp. 1–13.
- VAN DEN VELDE S, NEVENS F, VAN HEE P, VAN STEENBERGHE, P, QUIRYNEN, M. (2008) GC-MS analysis of breath odor compounds in liver patients. *J Chromatogr B Analyt Technol Biomed Life Sci*, 875(2), pp. 344–8.
- VITRY, A.I. (2007) Comparative assessment of four drug interaction compendia. *British Journal of Clinical Pharmacology*, 63(6), pp. 709–714.
- WHO (2019) World Health Organization Technical Report : Medication Safety in Polypharmacy. *The Third Global Patient Safety Challenge: Medication Without Harm, Webinar on Medication Safety*, pp. 1–63.

- WILLIAMS, S., LOUISSAINT, J., NIKIRK, S., BAJAJ, J.S. and TAPPER, E.B. (2021) Deprescribing medications that may increase the risk of hepatic encephalopathy: A qualitative study of patients with cirrhosis and their doctors. *United European Gastroenterology Journal*, 9(2), pp. 193–202.
- YOUNOSSE, Z.M., GUYATT, G., KIWI, M., BOPARAI, N. and KING, D. (1999) Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. *Gut*, 45(2), pp. 295–300.
- ZULHADJI, F.M., AMBAR, E. and ARMAJUN, L. (2023) Karakteristik Pasien Sirosis Hepatis Di RSUD Dr. H. Chasan Boesoirie Ternate. *E-Jurnal Medika Udayana*, 12(9), p. 96.

